← Eichor
Condition: Secondary To Immune Checkpoint Inhibitors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Secondary To Immune Checkpoint Inhibitors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Phase N/A · 1 location(s) · University Hospital, Montpellier · NCT06864481A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T
Phase 1 · 11 location(s) · AbbVie · NCT06487559Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer
Phase 2 · 2 location(s) · Soroka University Medical Center · NCT05502913Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Mon
Phase 3 · 36 location(s) · ImmunityBio, Inc. · NCT06745908Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
Phase N/A · 1 location(s) · Fudan University · NCT07705438ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06388031Naltrexone and Propranolol Combined With Immunotherapy
Phase 1 · 1 location(s) · Sarah Weiss · NCT05968690A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity
Phase 1/Phase 2 · 11 location(s) · Ipsen · NCT07213830A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigati
Phase 1/Phase 2 · 14 location(s) · BioNTech SE · NCT07079631Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Phase 2 · 1 location(s) · Kelly Fitzgerald, MD · NCT07043608Autoimmune Neurological Diseases and Those Secondary to Immunotherapy: Study of Immunological Mechanisms and Research In
NA · 4 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07456358Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Pat
Phase 2 · 1 location(s) · EuroCityClinic LLC · NCT07130032Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · Chuangzhen Chen · NCT07071103Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT04592211Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st
Phase 1/Phase 2 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT04691817Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Im
Phase 1/Phase 2 · 115 location(s) · AbbVie · NCT06772623Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
Phase N/A · 2 location(s) · Gene Solutions · NCT06227728Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untrea
Phase 3 · 81 location(s) · Iovance Biotherapeutics, Inc. · NCT05727904Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent a
Phase 2 · 13 location(s) · NATCO Pharma Ltd. · NCT05283226Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors
Phase N/A · 1 location(s) · University Hospital, Montpellier · NCT06470997A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06917092Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immu
Phase 3 · 207 location(s) · OSE Immunotherapeutics · NCT06472245Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Res
Phase N/A · 3 location(s) · Pamgene International B.V. · NCT06784778Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Phase 3 · 7 location(s) · Centre Leon Berard · NCT06346197Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectabl
Phase N/A · 1 location(s) · John Kirkwood · NCT07223411Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor
Phase 2 · 15 location(s) · Genelux Corporation · NCT06463665A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Chec
Phase 2/Phase 3 · 33 location(s) · Replimune, Inc. · NCT06581406
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.